Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers

Journal of Clinical Pharmacology

Volumn 38, Issue 5, 1998, Pages 433-436

  Vachharajani, Nimish N ^a   Shyu, Wen Chyi ^a   Mantha, Subbarao ^a   Park, Jong Soon ^a   Greene, Douglas S ^a   Barbhaiya, Rashmi H ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; IRBESARTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG SAFETY; FAT INTAKE; FOOD DRUG INTERACTION; GASTROENTERITIS; HEADACHE; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; THORAX PAIN; VERTIGO;

EID: 2642629706     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04449.x     Document Type: Article

References (20)

1. Benet LZ: Pharmacokinetics: absorption, distribution, and elimination. In, Katzung BG (ed.): Basic and Clinical Pharmacology. Norwalk, CT: Appleton and Lange, 1992;35-48.
2. Nies AS: Principles of drug therapy. In, Wyngarden JB, Smith LH (eds.): Cecil Textbook of Medicine. Philadelphia: WB Saunders, 1988;87-98.
3. Welling PG: Influence of food and diet on gastrointestinal drug absorption: a review. J Pharmacokinet Biopharm 1977;5:291-334.
4. Melander A: Influence of food on the bioavailability of drugs. Clin Pharmacokinet 1978;3:337-351.
5. Ribstein J, Sissmann J, Picard A, Bouroudian M, Mimran A: Effects of the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects (abstract). J Hypertens 1994;12(suppl 3):131.
6. Vachharajani N, Chang S-Y, Shyu WC, Greene D, Barbhaiya R: Absolute bioavailability of irbesartan, an angiotensin II receptor antagonist, in man (abstract). Pharm Res 1995;12(Suppl):418.
7. Pool JL, Guthrie RM, Littlejohn T, Raskin P, Shepherd AMM, Weber MA, et al: The antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension (abstract). Am J Hypertens 1996;9:152.
8. Criscione L, Bradley WA, Bühlmayer P, Whitebread S, Glazer R, Lloyd P, et al: Valsartan: preclinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 1995;13:230-250.
9. Schaefer KL, Porter JA: Angiotensin II receptor antagonists: the prototype losartan. Ann Pharmacother 1996;30:625-636.
10. Chang SY, Whigan DB, Vachharajani N, Patel R: High-performance liquid chromatographic assay for the quantification of irbesartan (SR 47436/BMS-186295) in human plasma and urine. J Chromatogr B 1997;702:149-155.
11. Gibaldi M, Perrier D: Pharmacokinetics. Second edition. New York: Marcel Dekker, 1982;409-417.
12. Farmen RH, Muniak JF, Pittman KA: Management of pharmacokinetic data using HP-3357/mainframe IBM interfacing. Drug Info J 1987;21:141-153.
13. Riegelman S, Collier P: The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1980;8:509-516.
14. Locke CS: An exact confidence interval from untransformed data for the ratio of two formulation means. J Pharmacokinet Biopharm 1984;12:649-665.
15. Koch GG: The use of nonparametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972; 28:577-584.
16. Williams L, Hill DP Jr, Davis JA, Lowenthal DT: The influence of food on the absorption and metabolism of drugs: an update. Eur J Drug Metab Pharmacokinet 1996;21:201-211.
17. Neuvonen PJ: Interactions with the absorption of tetracyclines. Drugs 1976;11:45-54.
18. Welling PG, Koch PA, Lau CC, Craig W: Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects. Antimicrob Agents Chemother 1977;11:462-469.
19. Shyu WC, Knupp CA, Pittman KA, Dunkle L, Barbhaiya R: Food-induced reduction in bioavailability of didanosine. Clin Pharmacol Ther 1991;50:503-507.
20. Levy RH, Pitlick WH, Troupin AS, Green JR, Neal JM: Pharmacokinetics of carbamazepine in normal man. Clin Pharmacol Ther 197;17:657-668.